| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,059 |
7,521 |
$714K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
6,064 |
3,697 |
$437K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,610 |
2,963 |
$406K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
8,611 |
6,900 |
$247K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,817 |
3,844 |
$228K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,358 |
2,651 |
$225K |
| 99215 |
Prolong outpt/office vis |
2,132 |
1,707 |
$197K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,654 |
3,313 |
$145K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,799 |
2,365 |
$101K |
| 87631 |
|
1,161 |
888 |
$91K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
336 |
322 |
$44K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
806 |
644 |
$36K |
| 96127 |
|
1,414 |
1,119 |
$19K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
404 |
357 |
$13K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
141 |
93 |
$9K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,265 |
834 |
$8K |
| 87634 |
|
207 |
151 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,978 |
999 |
$8K |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
344 |
213 |
$6K |
| 99000 |
|
5,718 |
2,339 |
$3K |
| 81002 |
|
1,598 |
1,036 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
189 |
185 |
$3K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
137 |
83 |
$3K |
| 99205 |
Prolong outpt/office vis |
22 |
14 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
130 |
98 |
$2K |
| 90686 |
|
111 |
74 |
$992.13 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
116 |
77 |
$963.18 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
61 |
59 |
$904.59 |
| 71046 |
Radiologic examination, chest; 2 views |
29 |
25 |
$843.87 |
| 81025 |
|
95 |
81 |
$670.44 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
399 |
325 |
$35.14 |
| 36415 |
Collection of venous blood by venipuncture |
14 |
13 |
$27.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
31 |
25 |
$23.40 |
| 94760 |
|
20 |
14 |
$12.70 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
120 |
80 |
$3.11 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
13 |
13 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
163 |
14 |
$0.00 |